Stock NTRA NATERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Natera, Inc.

Equities

NTRA

US6323071042

Real-time Estimate Cboe BZX
Other stock markets
 03:56:18 2024-05-02 pm EDT 		5-day change 1st Jan Change
93.48 USD -0.71% Intraday chart for Natera, Inc. +2.19% +48.91%
May. 01 Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage CI
Apr. 18 Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $824,092, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $16,694,485, According to a Recent SEC Filing
Natera Receives Commercial Insurance Coverage of Genetic Test for Transplant Risks
Natera Insider Sold Shares Worth $4,478,268, According to a Recent SEC Filing
Natera Narrows Q4 Loss, Revenue Rises; Shares Rise Late as 2024 Revenue Outlook Beats Consensus
Natera, Inc. Provides Earnings Guidance for the Year 2024
Natera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Medicare Extends Coverage of Natera's Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
Natera Insider Sold Shares Worth $6,514,371, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $2,383,129, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTRA Stock
  4. News Natera, Inc.
  5. Other languages